Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NILANJAN GHOSH

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1205035466
CMS profile
1223061
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$131,531.04

155 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $27,888.60 24
Celgene Corporation $17,601.36 22
Kite Pharma, Inc. $17,008.06 20
Genentech, Inc. $12,195.71 4
Seattle Genetics, Inc. $11,025.21 11
AbbVie, Inc. $10,877.75 12
Gilead Sciences, Inc. $9,470.98 19
Janssen Biotech, Inc. $7,350.70 11
Verastem, Inc. $6,359.66 9
Aurobindo Pharma USA, Inc. $4,843.92 7
Spectrum Pharmaceuticals Inc. $3,687.11 10
Pharmacyclics LLC, An AbbVie Company $3,116.35 5
EISAI INC. $105.63 1

Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NILANJAN GHOSH

NPI 1205035466 · CMS profile ID 1223061

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205035466?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NILANJAN GHOSH, NPI 1205035466, CMS profile ID 1223061. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205035466?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). NILANJAN GHOSH, NPI 1205035466, CMS profile ID 1223061. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205035466?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
NILANJAN GHOSH, NPI 1205035466, CMS profile ID 1223061, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1205035466?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

155 matching records · $131,531.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 155 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 155.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $23.1608/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672935703 CMS
Celgene Corporation $113.6908/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672936849 CMS
Celgene Corporation $25.0008/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672962837 CMS
Celgene Corporation $1,099.1008/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672963051 CMS
Seattle Genetics, Inc. $2,500.0008/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678800117 CMS
Pharmacyclics LLC, An AbbVie Company $600.0007/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665709381 CMS
Janssen Biotech, Inc. $11.3607/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658444161 CMS
AstraZeneca Pharmaceuticals LP $5,500.0007/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685881653 CMS
AbbVie, Inc. $60.5807/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648082933 CMS
AbbVie, Inc. $20.0007/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648082935 CMS
AbbVie, Inc. $3,150.0006/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648082917 CMS
AstraZeneca Pharmaceuticals LP $124.4606/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685361969 CMS
AstraZeneca Pharmaceuticals LP $723.1406/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685878817 CMS
Janssen Biotech, Inc. $2,200.0006/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658444157 CMS
AbbVie, Inc. $373.1006/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648082911 CMS
AbbVie, Inc. $116.3806/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648082931 CMS
AbbVie, Inc. $202.1306/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648082927 CMS
AbbVie, Inc. $116.3806/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648082929 CMS
Janssen Biotech, Inc. $96.9106/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658444152 CMS
Celgene Corporation $565.0006/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672850701 CMS
Gilead Sciences, Inc. $23.0005/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679342853 CMS
Gilead Sciences, Inc. $36.6405/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679342855 CMS
Gilead Sciences, Inc. $13.8805/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681517427 CMS
Gilead Sciences, Inc. $14.8705/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681517429 CMS
Gilead Sciences, Inc. $49.3005/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681517431 CMS
Seattle Genetics, Inc. $104.1505/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678800077 CMS
Kite Pharma, Inc. $3,900.0005/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662141707 CMS
Kite Pharma, Inc. $88.3705/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662141683 CMS
Kite Pharma, Inc. $719.6405/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662141711 CMS
AstraZeneca Pharmaceuticals LP $5,500.0005/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685285475 CMS
Gilead Sciences, Inc. $4,010.0005/21/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679258597 CMS
Janssen Biotech, Inc. $2,200.0005/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658444143 CMS
Celgene Corporation $265.0705/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672840829 CMS
Celgene Corporation $550.1005/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672869389 CMS
Janssen Biotech, Inc. $487.4905/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658444136 CMS
Janssen Biotech, Inc. $85.0005/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658444139 CMS
Gilead Sciences, Inc. $296.7205/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679342845 CMS
Gilead Sciences, Inc. $747.7305/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679342849 CMS
Gilead Sciences, Inc. $24.5905/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681517421 CMS
Gilead Sciences, Inc. $44.5905/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681517423 CMS
Gilead Sciences, Inc. $47.2305/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681517425 CMS
AstraZeneca Pharmaceuticals LP $101.1405/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685622123 CMS
AstraZeneca Pharmaceuticals LP $676.3505/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685915317 CMS
AstraZeneca Pharmaceuticals LP $300.0005/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685085831 CMS
AstraZeneca Pharmaceuticals LP $300.0005/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685717977 CMS
Celgene Corporation $3,955.0005/02/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672797415 CMS
Pharmacyclics LLC, An AbbVie Company $600.0004/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705879 CMS
Kite Pharma, Inc. $6.0304/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662142173 CMS
Kite Pharma, Inc. $4.6104/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662142175 CMS
Kite Pharma, Inc. $4,050.0004/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662142357 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $131,531.04 155
PY2020 $103,805.47 60
PY2021 $84,805.44 59
PY2022 $54,616.42 62
PY2023 $45,813.81 39
PY2024 $44,095.70 53
PY2025 $45,099.48 47

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,307.30 5
PY2025 Principal investigator $578,284.72 16
PY2024 Principal investigator $744,155.30 65
PY2023 Recipient $350.00 2
PY2023 Principal investigator $1,366,338.45 65
PY2022 Recipient $4,450.00 6
PY2022 Principal investigator $187,988.92 50
PY2021 Recipient $4,262.33 3
PY2021 Principal investigator $627,370.00 163
PY2020 Principal investigator $1,261,300.44 134
PY2019 Recipient $2,461.00 2
PY2019 Principal investigator $1,073,264.50 134

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $65,062.50 12/18/2025 Non-covered Recipient Entity
SWOG CLINICAL TRIALS INITIATIVE LLC
Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma, S2308 No dispute reported 06/30/2026 1211660792
Recipient F. Hoffmann-La Roche AG $616.07 12/12/2025 Covered Recipient Physician Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211538056
Recipient F. Hoffmann-La Roche AG $460.12 12/10/2025 Covered Recipient Physician Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211538061
Recipient ABBVIE INC. $725.00 12/05/2025 Covered Recipient Physician A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL No dispute reported 06/30/2026 1202398474
Principal investigator 1 ABBVIE INC. $1,784.58 12/04/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202528648
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $625.35 11/14/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH UNION
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 1223263776
Principal investigator 1 ABBVIE INC. $3,398.32 11/05/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202521693
Principal investigator 1 ABBVIE INC. $256.16 09/04/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH UNION
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. No dispute reported 06/30/2026 1202404384
Principal investigator 1 ABBVIE INC. $65.63 09/04/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH UNION
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. No dispute reported 06/30/2026 1202404387
Principal investigator 1 Incyte Corporation $298.00 08/15/2025 Covered Recipient Teaching Hospital
Atrium Health Cabarrus
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) No dispute reported 06/30/2026 1240480181
Principal investigator 1 ABBVIE INC. $256.16 07/03/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH UNION
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. No dispute reported 06/30/2026 1202404380
Principal investigator 1 AstraZeneca Pharmaceuticals LP $105,369.32 06/25/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES CLINICAL TRIALS OFFIC
A Modular Phase I and II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium) No dispute reported 06/30/2026 1185543478
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $316,826.42 06/17/2025 Covered Recipient Teaching Hospital
Atrium Health Cabarrus
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) No dispute reported 06/30/2026 1236001789
Recipient F. Hoffmann-La Roche AG $781.11 06/17/2025 Covered Recipient Physician To evaluate safety tolerability and efficacy of TCB No dispute reported 06/30/2026 1211538065
Recipient ABBVIE INC. $725.00 06/12/2025 Covered Recipient Physician A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL No dispute reported 06/30/2026 1202398471
Principal investigator 1 ABBVIE INC. $256.16 04/24/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH UNION
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. No dispute reported 06/30/2026 1202404372
Principal investigator 1 ABBVIE INC. $179.32 04/24/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH UNION
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. No dispute reported 06/30/2026 1202404377
Principal investigator 1 Genentech, Inc. $10,664.71 04/11/2025 Covered Recipient Teaching Hospital
Atrium Health Cabarrus
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211540145
Principal investigator 1 Genentech, Inc. $4,246.82 02/13/2025 Covered Recipient Teaching Hospital
Atrium Health Cabarrus
To evaluate safety tolerability and efficacy of TCB No dispute reported 06/30/2026 1211540142
Principal investigator 1 ABBVIE INC. $29,900.02 02/06/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202448182
Principal investigator 1 ABBVIE INC. $39,095.25 01/23/2025 Covered Recipient Teaching Hospital
CAROLINAS MEDICAL CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202407265